Carcinoid Tumor: A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)Malignant Carcinoid Syndrome: A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)Carcinoid Heart Disease: Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.Ileal Neoplasms: Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Hydroxyindoleacetic AcidIntestinal Neoplasms: Tumors or cancer of the INTESTINES.Chromogranins: A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.Octreotide: A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.Chromogranin A: A type of chromogranin which was first isolated from CHROMAFFIN CELLS of the ADRENAL MEDULLA but is also found in other tissues and in many species including human, bovine, rat, mouse, and others. It is an acidic protein with 431 to 445 amino acid residues. It contains fragments that inhibit vasoconstriction or release of hormones and neurotransmitter, while other fragments exert antimicrobial actions.ACTH Syndrome, Ectopic: Symptom complex due to ACTH production by non-pituitary neoplasms.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Paraneoplastic Endocrine Syndromes: Syndromes resulting from inappropriate production of HORMONES or hormone-like materials by NEOPLASMS in non-endocrine tissues or not by the usual ENDOCRINE GLANDS. Such hormone outputs are called ectopic hormone (HORMONES, ECTOPIC) secretion.Proctoscopy: Endoscopic examination, therapy or surgery of the rectum.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Enterochromaffin Cells: A subtype of enteroendocrine cells found in the gastrointestinal MUCOSA, particularly in the glands of PYLORIC ANTRUM; DUODENUM; and ILEUM. These cells secrete mainly SEROTONIN and some neuropeptides. Their secretory granules stain readily with silver (argentaffin stain).Liver Neoplasms: Tumors or cancer of the LIVER.3-Iodobenzylguanidine: A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.Ampulla of Vater: A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Lung Neoplasms: Tumors or cancer of the LUNG.Receptors, Somatostatin: Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.Somatostatin: A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.Indium Radioisotopes: Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.Cell Line, Tumor: A cell line derived from cultured tumor cells.Appendix: A worm-like blind tube extension from the CECUM.Jejunal Neoplasms: Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.Duodenoscopy: Endoscopic examination, therapy or surgery of the luminal surface of the duodenum.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.Stomach Neoplasms: Tumors or cancer of the STOMACH.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Paraganglioma, Extra-Adrenal: A relatively rare, usually benign neoplasm originating in the chemoreceptor tissue of the CAROTID BODY; GLOMUS JUGULARE; GLOMUS TYMPANICUM; AORTIC BODIES; and the female genital tract. It consists histologically of rounded or ovoid hyperchromatic cells that tend to be grouped in an alveolus-like pattern within a scant to moderate amount of fibrous stroma and a few large thin-walled vascular channels. (From Stedman, 27th ed)Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Polyps: Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Ear Neoplasms: Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).Appendectomy: Surgical removal of the vermiform appendix. (Dorland, 28th ed)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Digestive System Neoplasms: Tumors or cancer of the DIGESTIVE SYSTEM.Flushing: A transient reddening of the face that may be due to fever, certain drugs, exertion, stress, or a disease process.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Synaptophysin: A MARVEL domain-containing protein found in the presynaptic vesicles of NEURONS and NEUROENDOCRINE CELLS. It is commonly used as an immunocytochemical marker for neuroendocrine differentiation.Enterochromaffin-like Cells: Neuroendocrine cells in the glands of the GASTRIC MUCOSA. They produce HISTAMINE and peptides such as CHROMOGRANINS. ECL cells respond to GASTRIN by releasing histamine which acts as a paracrine stimulator of the release of HYDROCHLORIC ACID from the GASTRIC PARIETAL CELLS.Phosphopyruvate Hydratase: A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.Rectal Neoplasms: Tumors or cancer of the RECTUM.IodobenzenesAdenocarcinoma: A malignant epithelial tumor with a glandular organization.Multiple Endocrine Neoplasia Type 1: A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).Serotonin: A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.Apudoma: A general term collectively applied to tumors associated with the APUD CELLS series, irrespective of their specific identification.Meckel Diverticulum: A congenital abnormality characterized by the outpouching or sac formation in the ILEUM. It is a remnant of the embryonic YOLK SAC in which the VITELLINE DUCT failed to close.Adenoma, Islet Cell: A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.Wilms Tumor: A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Glomus Tumor: A blue-red, extremely painful vascular neoplasm involving a glomeriform arteriovenous anastomosis (glomus body), which may be found anywhere in the skin, most often in the distal portion of the fingers and toes, especially beneath the nail. It is composed of specialized pericytes (sometimes termed glomus cells), usually in single encapsulated nodular masses which may be several millimeters in diameter (From Stedman, 27th ed). CHEMODECTOMA, a tumor of NEURAL CREST origin, is also sometimes called a glomus tumor.Muridae: A family of the order Rodentia containing 250 genera including the two genera Mus (MICE) and Rattus (RATS), from which the laboratory inbred strains are developed. The fifteen subfamilies are SIGMODONTINAE (New World mice and rats), CRICETINAE, Spalacinae, Myospalacinae, Lophiomyinae, ARVICOLINAE, Platacanthomyinae, Nesomyinae, Otomyinae, Rhizomyinae, GERBILLINAE, Dendromurinae, Cricetomyinae, MURINAE (Old World mice and rats), and Hydromyinae.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. (1/854)

Endocrine pancreatic tumors (EPT) and neuroendocrine tumors (NET) occur sporadically and rarely in association with multiple endocrine neoplasia type 1 (MEN1). We analyzed the frequency of allelic deletions and mutations of the recently identified MEN1 gene in 53 sporadic tumors including 30 EPT and 23 NET (carcinoids) of different locations and types. Allelic deletion of the MEN1 locus was identified in 18/49 (36.7%) tumors (13/30, 43.3% in EPT and 5/19, 26.3% in NET) and mutations of the MEN1 gene were present in 8/52 (15.3%) tumors (4/30 (13.3%) EPT and 4/22 (18.1%) NET). The somatic mutations were clustered in the 5' region of the coding sequence and most frequently encompassed missense mutations. All tumors with mutations exhibited a loss of the other allele and a wild-type sequence of the MEN1 gene in nontumorous DNA. In one additional patient with a NET of the lung and no clinical signs or history of MEN1, a 5178-9G-->A splice donor site mutation in intron 4 was identified in both the tumor and blood DNA, indicating the presence of a thus far unknown MEN1 syndrome. In most tumor groups the frequency of allelic deletions at 11q13 was 2 to 3 times higher than the frequency of identified MEN1 gene mutations. Some tumor types, including rare forms of EPT and NET of the duodenum and small intestine, exhibited mutations more frequently than other types. Furthermore, somatic mutations were not restricted to foregut tumors but were also detectable in a midgut tumor (15.2% versus 16.6%). Our data indicate that somatic MEN1 gene mutations contribute to a subset of sporadic EPT and NET, including midgut tumors. Because the frequency of mutations varies significantly among the investigated tumor subgroups and allelic deletions are 2 to 3 times more frequently observed, factors other than MEN1 gene inactivation, including other tumor-suppressor genes on 11q13, may also be involved in the tumorigenesis of these neoplasms.  (+info)

Carcinoids of the common bile duct: a case report and literature review. (2/854)

Carcinoids of the extrahepatic bile ducts and particularly the common bile duct are extremely rare. A 65-year-old woman presented with obstructive jaundice. Laboratory and imaging studies gave results that were consistent with an obstructing lesion in the common bile duct. In this case, a stent was inserted initially to decompress the bile ducts. Subsequently a laparotomy and pancreaticoduodenectomy were performed and a tissue diagnosis of carcinoid of the common bile duct was made. The patient was well with no evidence of recurrence 17 months postoperatively. The authors believe this is the 19th reported case of an extrahepatic bile duct carcinoid.  (+info)

Primary hepatic carcinoid in a renal transplant patient. (3/854)

There seems to be a world-wide increase in the incidence of tumors among immunosuppressed patients. Of 1350 renal allografts transplanted in the past 23 years at the Department of Transplantation and Surgery, 56 cases were malignant tumors. The case of a 58-year-old female patient is reported, with disseminated primary carcinoid in the liver detected 86 days after renal transplantation. According to the literature only 39 patients with primary liver carcinoids have been reported until 1997, but this is the first where the carcinoid developed in an immunosuppressed patient. The rapid progression of the carcinoid could be associated with the immunosuppression.  (+info)

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. (4/854)

PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS: Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.  (+info)

Primary carcinoid tumor of the testis: immunohistochemical, ultrastructural and DNA flow cytometric study of two cases. (5/854)

Primary testicular carcinoid tumor, occupying 0.23% of testicular neoplasm, is a rare and indolent neoplasm with the potential for distant metastasis. We present two cases of primary pure carcinoid tumor of the testis. Both patients were 36 years old. Physical examination revealed testicular mass with and without tenderness. The preoperative serum levels of beta-human chorionic gonadotropin and alpha-fetoprotein were normal and neither patient had carcinoid syndrome. The tumors measured 7.5x6x4 cm and 5.5x5x4 cm in size. Histologically, immunohistochemically and ultrastructurally, the tumors showed typical features of the carcinoid tumor. Case 1 showed extensive tumor necrosis and vascular invasion. DNA flow cytometric analysis showed aneuploidy with DNA index of 1.47 and S+G2M of 14.0% in case 1 and tetraploidy with DNA index of 1.96 and S+G2M of 22.1% in case 2. Both patients have been well without any signs of metastasis after operation for 24 months in case 1 and for 16 months in case 2.  (+info)

Library of sequence-specific radioimmunoassays for human chromogranin A. (6/854)

BACKGROUND: Human chromogranin A (CgA) is an acidic protein widely expressed in neuroendocrine tissue and tumors. The extensive tissue- and tumor-specific cleavages of CgA at basic cleavage sites produce multiple peptides. METHODS: We have developed a library of RIAs specific for different epitopes, including the NH2 and COOH termini and three sequences adjacent to dibasic sites in the remaining part of CgA. RESULTS: The antisera raised against CgA(210-222) and CgA(340-348) required a free NH2 terminus for binding. All antisera displayed high titers, high indexes of heterogeneity ( approximately 1.0), and high binding affinities (Keff0 approximately 0.1 x 10(12) to 1.0 x 10(12) L/mol), implying that the RIAs were monospecific and sensitive. The concentration of CgA in different tissues varied with the assay used. Hence, in a carcinoid tumor the concentration varied from 0.5 to 34.0 nmol/g tissue depending on the specificity of the CgA assay. The lowest concentration in all tumors was measured with the assay specific for the NH2 terminus of CgA. This is consistent with the relatively low concentrations measured in plasma from carcinoid tumor patients by the N-terminal assay, whereas the assays using antisera raised against CgA(210-222) and CgA(340-348) measured increased concentrations. CONCLUSION: Only some CgA assays appear useful for diagnosis of neuroendocrine tumors, but the entire library is valuable for studies of the expression and processing of human CgA.  (+info)

Review article: current status of gastrointestinal carcinoids. (7/854)

Carcinoid tumours are enigmatic, slow growing malignancies which occur most frequently (74%) in the gastrointestinal tract. In recent years, it has become apparent that the term 'carcinoid' represents a wide spectrum of different neoplasms originating from a variety of different neuroendocrine cell types. Carcinoid lesions are usually identified histologically by their affinity for silver salts, by general neuroendocrine markers, or more specifically by immunocytochemistry using antibodies against their specific cellular products. Within the gut, the most frequent sites are the small bowel (29%), the appendix (19%) and rectum (13%). Clinical manifestations are often vague or absent. Nevertheless, in approximately 10% of patients the tumours secrete bioactive mediators which may engender various elements of characteristic carcinoid syndrome. In many instances the neoplasms are detected incidentally at the time of surgery for other gastrointestinal disorders. The tendency for metastatic spread correlates with tumour size, and is substantially higher in lesions larger than 2.0 cm. An association with noncarcinoid neoplasms is ascribed in 8-17% of lesions. Treatment consists of radical surgical excision of the tumour, although gastric (type I and II) and rectal carcinoids may be managed with local excision. Overall 5-year survival is excellent for carcinoids of the appendix (86%) and rectum (72%), whereas small intestinal (55%), gastric (49%) and colonic carcinoids (42%) exhibit a far worse prognosis.  (+info)

Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. (8/854)

BACKGROUND: Type 1 gastric carcinoids are associated with hypergastrinaemia and chronic atrophic gastritis, type 2 occur in patients with multiple endocrine neoplasia type 1 combined with Zollinger-Ellison syndrome, and type 3 lack any relation to hypergastrinaemia. Type 1 tumours are usually benign whereas type 3 are highly malignant. AIMS: To identify possible tumour markers in patients with gastric carcinoids. PATIENTS/METHOD: Nine patients with type 1, one with type 2, and five with type 3 were evaluated with regard to symptoms, hormone profile, and prognosis. RESULTS: Plasma chromogranin A was increased in all patients but was higher (p < 0.01) in those with type 3 than those with type 1 carcinoids. All patients with type 3 carcinoids died from metastatic disease, but none of the type 1 patients died as a result of their tumours. One type 1 patient with a solitary liver metastasis received interferon alpha and octreotide treatment. Nine months later, the metastasis was no longer detectable. She is still alive eight years after diagnosis, without recurrent disease. This represents the only reported case of foregut carcinoid with an unresectable liver metastasis that seems to be have been cured by biotherapy. CONCLUSIONS: Plasma chromogranin A appears to be a valuable tumour marker for all types of gastric carcinoid. Combination therapy with interferon alpha and octreotide may be beneficial in patients with metastasising type 1 gastric carcinoids.  (+info)

*Pulmonary carcinoid tumour

... is a neuroendocrine tumour of the lung. There are two types: Typical pulmonary carcinoid tumour ... Atypical pulmonary carcinoid tumour Lung carcinoids (cancer.org). ...

*Atypical pulmonary carcinoid tumour

... is a subtype of pulmonary carcinoid tumor. It is an uncommon low-grade malignant lung mass ... Typical pulmonary carcinoid tumor Typical pulmonary carcinoid lacks comedo-like necrosis, and has < 0.2 mitotic figures/HPF.. ... It is also known as "atypical lung carcinoid tumour", " atypical lung carcinoid" or "moderately differentiated neuroendocrine ... 5%. The 5 year survival is 49-69%. Atypical carcinoid tumors have increased mitotic activity (2-10 per 10 HPF), nuclear ...

*Typical pulmonary carcinoid tumour

It is also known as typical lung carcinoid tumour, lung carcinoid, and typical lung carcinoid. Lung carcinoids typically ... Typical pulmonary carcinoid tumour is a subtype of pulmonary carcinoid tumour. It is an uncommon low-grade malignant lung mass ... Typical carcinoids are usually treated with surgical excision. Pulmonary tumor Lung cancer Atypical pulmonary carcinoid tumour ... The differential diagnosis of typical pulmonary carcinoid tumour includes: atypical pulmonary carcinoid tumour, pulmonary ...

*Cancer syndrome

Genetic testing should be considered with adrenocortical carcinoma; carcinoid tumors; diffuse gastric cancer; fallopian tube/ ... Other tumors increased in frequency include; osteomas, adrenal adenomas and carcinomas, thyroid tumors and desmoid tumors. The ... Hepatic tumors and squamous cell carcinomas of the esophagus, oropharynx and uvula are solid tumors commonly linked to FA. ... endolymphatic sac tumors and epididymal papillary cystadenomas. VHL results from a mutation in the von Hippel-Lindau tumor ...

*List of OMIM disorder codes

CPN1 Carcinoid tumors, intestinal; 114900; SDHD Cardiac arrhythmia, ankyrin-B-related; 600919; ANK2 Cardiac conduction defect, ... KRT4 Wilms tumor 2; 194071; H19 Wilms tumor; 194070; BRCA2 Wilms tumor, somatic; 194070; GPC3 Wilms tumor, type 1; 194070; WT1 ... PIK3CA Gastrointestinal stromal tumor, somatic; 606764; KIT Gastrointestinal stromal tumor, somatic; 606764; PDGFRA Gaucher ... SLC34A2 Testicular tumor, sporadic; 273300; STK11 Tetra-amelia, autosomal recessive; 273395; WNT3 Tetralogy of Fallot; 187500; ...

*Strumal carcinoid

... a neuroendocrine tumour (carcinoid). Struma ovarii Teratoma Gorin, I.; Sastre-Garau, X. (Jun 2008). "Strumal carcinoid tumor of ... The strumal carcinoid is a type of monodermal teratoma with histomorphologic features of (1) the thyroid gland and (2) ... Feb 1992). "Ovarian strumal carcinoid in association with multiple endocrine neoplasia, type IIA". Arch Pathol Lab Med. 116 (2 ...

*Infections associated with diseases

Chia, J.; Chia, A.; El-Habbal, R. (2011). "Carcinoid tumour associated with enterovirus infection". Journal of Clinical ... Söderberg-Nauclér, Cecilia (2015). "Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options ... and Association with Human Tumors". Polyomaviruses and Human Diseases. Advances in Experimental Medicine and Biology. 577. pp. ...

*5-Hydroxyindoleacetic acid

Tumors derived from hindgut cells (rectal carcinoid) rarely produce excess serotonin or 5-HIAA. Of 75 patients with carcinoid ... 5-HIAA may be normal with nonmetastatic carcinoid tumor and may be normal even with the carcinoid syndrome, particularly in ... Serotonin, and consequently 5-HIAA, are produced in excess by most carcinoid tumors, especially those producing the carcinoid ... Tumors from midgut cells, such as ileal carcinoid usually contain and release large quantities of serotonin. These amounts may ...

*Fenclonine

Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. (Am J Med. ... It has been used experimentally to treat carcinoid syndrome, but the side effects, mostly hypersensitivity reactions and ...

*Neuroendocrine tumor

Carcinoid Tumor Overview. healthcommunities.com Kvols LK. 2002. Carcinoid Tumors and the Carcinoid Syndrome: What's New in the ... Parathyroid tumors Thymus and mediastinal carcinoid tumors Pulmonary neuroendocrine tumorsbronchus pulmonary carcinoid tumors: ... Small intestinal neuroendocrine tumors were first distinguished from other tumors in 1907. They were named carcinoid tumors ... In malignant carcinoid tumors with carcinoid syndrome, the median survival has improved from two years to more than eight years ...

*Kidney cancer

"Carcinoid tumor of the renal pelvis: consideration on the histogenesis". Pathol. Int. 58 (1): 51-4. doi:10.1111/j.1440- ... The majority of kidney cancers reported in children are Wilms' tumors. These tumors can begin to grow when a fetus is still ... tumor, usually is reported in children under the age of 5. Mixed epithelial stromal tumor Rarely, some other types of cancer ... Clear cell adenocarcinoma Transitional cell carcinoma Inverted papilloma Renal lymphoma Teratoma Carcinosarcoma Carcinoid tumor ...

*Apudoma

VIPoma carcinoid tumor "IARC TP53 DATABASE - Morphology list". Archived from the original on 15 October 2007. Retrieved 2007-09 ... In pathology, an apudoma is an endocrine tumour that arises from an APUD cell from structures such as the ampulla of Vater,. ... see neuroendocrine tumor). The term dates back to at least 1975. Because the label "Apudoma" is very general, it is preferred ...

*PAK3

... is overexpressed in neuroendocrine/carcinoids tumors. PAK3 has been shown to be important for synapse formation and ... "p21-activated kinase 3 is overexpressed in thymic neuroendocrine tumors (carcinoids) with ectopic ACTH syndrome and ...

*Scintigraphy

2007). "Anatomic and functional imaging of metastatic carcinoid tumors". Radiographics. 27 (2): 455-77. doi:10.1148/rg. ... The MIBG scan detects adrenergic tissue and thus can be used to identify the location of tumors such as pheochromocytomas and ... a tumor, or another cause. It can also diagnose gallbladder diseases, e.g. bile leaks of biliary fistulas. In cholescintigraphy ...

*Seminal colliculus

Urethral carcinoid tumors have been reported at the verumontanum. The structure tends to migrate caudally, or downward, in ... Maxwell Smith, M Scott Lucia, Priya N Werahera and Francisco G La Rosa Carcinoid tumor of the verumontanum (colliculus ...

*Iobenguane

2007). "Anatomic and functional imaging of metastatic carcinoid tumors". Radiographics. 27 (2): 455-77. doi:10.1148/rg. ... With I-131 it can also be used to eradicate tumor cells that take up and metabolize norepinephrine. Thyroid blockade with ( ... link) CS1 maint: Multiple names: authors list (link) FDA grants priority review to Azedra for rare neuroendocrine tumors Jan ... It localizes to adrenergic tissue and thus can be used to identify the location of tumors such as pheochromocytomas and ...

*Cecum

A cecal carcinoid tumor is a carcinoid tumor of the cecum. An appendiceal carcinoid tumor (a carcinoid tumor of the appendix) ... is sometimes found next to a cecal carcinoid.[citation needed] A cecum is present in most amniote species, and also in lungfish ...

*Carcinoid

... tumors of the midgut (jejunum, ileum, appendix, and cecum) are associated with carcinoid syndrome. Carcinoid tumors ... Carcinoid tumors are also found in the lungs. Metastasis of carcinoid can lead to carcinoid syndrome. This is due to the over- ... Carcinoid (also carcinoid tumor) is a slow-growing type of neuroendocrine tumor originating in the cells of the neuroendocrine ... carcinoid tumors are the most common malignancy of the appendix. Carcinoid tumors may rarely arise from the ovary or thymus. ...

*Pulmonary neuroendocrine tumor

Pulmonary neuroendocrine tumors include a spectrum of tumors from the low-grade typical pulmonary carcinoid tumor and ... Atypical pulmonary carcinoid tumour (AC; intermediate-grade) High-grade pulmonary neuroendocrine tumor Small cell lung cancer ( ... Typical pulmonary carcinoid tumour (TC; low-grade); Intermediate-grade pulmonary neuroendocrine tumor: ... Multiple endocrine neoplasia type I (MEN1)can be found in carcinoid tumor patients, but not those with LCNEC and SCLC. Genetic ...

*Lung cancer

Rare subtypes include carcinoid tumors, bronchial gland carcinomas and sarcomatoid carcinomas. The lung is a common place for ... By studying samples at different points of tumor development, the researchers hope to identify the changes that drive tumor ... Tumors in the top of the lung, known as Pancoast tumors, may invade the local part of the sympathetic nervous system, leading ... Malignant lung tumors made up only 1% of all cancers seen at autopsy in 1878, but had risen to 10-15% by the early 1900s. Case ...

*Bradykinin

... is also released by carcinoid tumors, and results in asthma-like symptoms. Hypotensive transfusion reaction Marcos- ...

*AMY2B

1989). "A novel type of human alpha-amylase produced in lung carcinoid tumor". Gene. 76 (1): 11-8. doi:10.1016/0378-1119(89) ...

*MEN1

Consequently, the carcinoid tumors with MEN1 gene inactivation in the study were considered to be characterized by more ... In a study of 12 sporadic carcinoid tumors of the lung, five cases involved inactivation of both copies of the MEN1 gene. Of ... Insulinomas are neuroendocrine tumors of the pancreas with an incidence of 0.4 % which usually are benign solitary tumors but 5 ... Less frequently, neuroendocrine tumors of lung, thymus, and stomach or non-endocrine tumors such as lipomas, angiofibromas, and ...

*Enteroendocrine cell

Rare and slow growing carcinoid and non-carcinoid tumors develop from these cells. When a tumor arises it has the capacity to ... Warner, RR (May 2005). "Enteroendocrine tumors other than carcinoid: a review of clinically significant advances". ... APUD cells Neuroendocrine tumors Rehfeld, Jens F (1998). "The New Biology of Gastrointestinal Hormones". Physiol. Rev. 78: 1087 ...

*Otto Lubarsch

Among other contributions to medical knowledge, Lubarsch provided the first detailed description of carcinoid tumors. He ... In 1888 Lubarsch provided the first detailed description of carcinoid tumors during autopsies of two male "patients", however ... Otto Lubarsch at Who Named It Gastrointestinal Neuroendocrine Tumors Works by or about Otto Lubarsch at Internet Archive Media ... "Carninoid Tumors". The Oncologist. 13 (12): 1255-1269. doi:10.1634/theoncologist.2008-0207. PMC 2901509 . PMID 19091780. ...

*Appendix cancer

Breast cancer, colon cancer, and tumors of the female genital tract may metastasize to the appendix. Small carcinoids (. ... Gastrointestinal stromal tumors are rare tumors with malignant potential. Primary lymphomas can occur in the appendix. ...
A 49-year-old man was admitted to our hospital complaining of a large hepatic tumor with edema in the lower extremities. The patient had suffered from hypertension and bronchial asthma in his twenties and from cutaneous flushing in the face in his thirties. Echocardiography revealed tricuspid valve regurgitation and marked dilatation of the right ventricle. In an exploratory laparotomy, a 15 cm-size hepatic tumor was located in the right lobe with multiple satellite lesions in both lobes of the liver. Peritoneal disseminations were present. The tumor was histologically and immunohistochemically diagnosed to be a carcinoid tumor. The levels of serum serotonin and urinary 5-hydroxyindoleacetic acid (5-HIAA) were found to be significantly high. Imaging modalities and intraoperative findings showed no evidence of any tumors elsewhere. These findings led us to the diagnosis of a primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease. The patient has been treated with ...
Many risk factors may increase your chance of developing gastrointestinal carcinoid tumors. This guide will help you learn about possible causes of gastrointestinal carcinoid tumors.
Pulmonary carcinoids are rare neuroendocrine tumours of the lung. The molecular alterations underlying the pathogenesis of these tumours have not been systematically studied so far. Here we perform gene copy number analysis (n=54), genome/exome (n=44) and transcriptome (n=69) sequencing of pulmonary carcinoids and observe frequent mutations in chromatin-remodelling genes. Covalent histone modifiers and subunits of the SWI/SNF complex are mutated in 40 and 22.2% of the cases, respectively, with MEN1, PSIP1 and ARID1A being recurrently affected. In contrast to small-cell lung cancer and large-cell neuroendocrine lung tumours, TP53 and RB1 mutations are rare events, suggesting that pulmonary carcinoids are not early progenitor lesions of the highly aggressive lung neuroendocrine tumours but arise through independent cellular mechanisms. These data also suggest that inactivation of chromatin-remodelling genes is sufficient to drive transformation in pulmonary carcinoids.
Carcinoid tumors are rare. In early stage disease they may cause either no or few nonspecific symptoms. Therefore, patients with carcinoid tumors most often present late in the course of their illness when there is already progression to an incurable state as a result of metastatic disease. At present there are neither practical population screening tests nor effective therapies and hence the 5 year survival rate is low. Due to the rareness of sporadic carcinoid tumors, large scale genetic analysis and development of sensitive and specific diagnostic tests have not been successful. While kindreds with familial carcinoid tumors that are not ascribable to known genetic syndromes are exceedingly rare, they provide a unique opportunity to facilitate the identification of the responsible gene mutation. In addition, the mutated gene in the rare familial form may also underlie the origin of the more common sporadic occurrence of carcinoid tumors. We propose to study families in which there are at least ...
Carcinoid tumors represent an interesting family of tumors that are derived from neuroendocrine cells. With few exceptions, carcinoid tumors comprise a tiny fraction of tumors within any specific organ (11). These tumors were first described by Langhans (12) but were not described in detail until Lubarsch (13) described them in 1888. The name karzinoide was not used until 1907 by Oberndorfer (14), and was chosen to reflect his opinion that these were benign tumors. However, these tumors have a wide range of clinical presentations and diverse outcomes from benign to malignant. In the testis and in other organs, carcinoid tumors may behave aggressively and some investigators (15) have suggested that a designation of "neuroendocrine carcinoma" is more appropriate than "carcinoid tumor"; other investigators disagree with this approach (16).. The histogenesis of testicular carcinoid tumor has been a matter of debate (17). There is a strong rationale for the concept that testicular carcinoid tumor is ...
Diagnosis and treatment of the gastrointestinal carcinoid tumors with stenosis with endoscopic bougienage/ stenting (costs for program #154809) ✔ Academic Hospital Harlaching ✔ Department of Pulmonology, Gastroenterology, Internal Intensive Medicine and Respiratory Medicine ✔ BookingHealth.com
For gastrointestinal carcinoid tumors that have not spread to distant sites, surgery is usually the primary or first treatment. Learn about other treatment options here.
METHODS AND PROCEDURES From January 2001 to December 2010, total 299 patients with colorectal carcinoid tumors were treated at the National Cancer Center, South Korea. Among of them, we excluded patients who had metastatic disease(n=10), who underewent radical operation(n=33), who were diagnosed in other hospitals(n=83) and who had colon carcinoid tumors(n=3). Finally, 170 patients with 175 rectal carcinoid tumors, who treated with local excision including endoscopic resection and surgical resection were enrolled this study. A pathologically complete resection(P-CR) was defined as an en bloc resection with tumor-free lateral and deep margin. Local treatment methods were classified to conventional polypectomy including strip biopsy, snare polypectomy and hot biopsy, advanced endoscopic techniques including endoscopic mucosal resection with cap(EMR-C) and endoscopic submucosal dissection(ESD) and surgical local excision including transanal excision(TAE) and transanal endoscopic microsurgery(TEM). ...
Immunohistochemical studies showed that the tumor cells were reactive for chromogranin (Fig. 2b), TTF1, cytokeratin (CK)7, synaptophysin, neuron-specific enolase, focally positive for CD56 (Fig. 2c) and negative for S100 protein and CK20 (Fig. 2d).. Based on the patients history and scalp biopsy, a final diagnosis of skin metastasis of pulmonary atypical carcinoid tumor was made.. Cutaneous metastases (CM) occur in 0.7-9% of all patients with internal malignancies and metastatic tumor from carcinoid tumors represent an even smaller subset. Although visceral metastases of carcinoid tumors are common, CM are rare, and most CM are of bronchial origin.[1-3]. Cutaneous metastases tend to occur on the upper extremities, but can be found anywhere in the skin. CM are often painful and the pain is secondary to perineural invasion or to the release of vasoactive substances and peptide hormones, such as kallikrein and serotonin by carcinoid cells.[1-3] In our patient, we have assumed that the pain was ...
Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma. The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the results of published studies to generate treatment recommendations and identify areas for future research. Surgery remains the standard of care for medically operable disease. Histology plays the most important role in determining the role of adjuvant radiation. Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal status. Resected atypical carcinoids and large-cell neuroendocrine carcinomas have a significant risk of local failure, for which adjuvant radiation likely improves local control. Definitive radiation is warranted in unresectable disease. Palliative radiation for symptomatic lesions has demonstrated efficacy for all histologies.
What are Carcinoid Tumors?. The neuroendocrine system is made up of cells that "connect" the nervous system and the endocrine system. Neuroendocrine cells release hormones (sometimes called peptides) into the circulatory system in response to a stimulus received from the nervous system. These specialized cells are scattered throughout the organs in the body and are the cells that give rise to neuroendocrine tumors.. Neuroendocrine tumors (NETs) include both carcinoid tumors and pancreatic endocrine tumors (PETs). Carcinoid tumors represent the largest number of neuroendocrine tumors and pose a significant challenge to the clinician because they produce a unique clinical syndrome. Consequently, their diagnosis is difficult and often delayed. The clinician requires a high index of suspicion and confirmation with biochemical tests in order to establish their diagnosis. Because the majority of neuroendocrine tumors of the pancreas and carcinoid tumors that involve the wall of the gut have similar ...
Gastrointestinal carcinoid, also called carcinoid tumor, is the most common primary tumor of the small bowel and appendix. Gastrointestinal carcinoid accounts for more than 95% of all carcinoids.
Bronchial carcinoid tumors are very rare pulmonary neoplasms. They usually present with pulmonary symptoms or paraneoplastic syndromes. Typical (well-differentiated) tumors are usually indolent with survival exceeding 90% after resection. Atypical carcinoids have a worse prognosis. They are much more likely to recur locally or to have distant metastases. This case report describes a patient who presented with abdominal pain and hepatic lesions who was subsequently diagnosed to have bronchial carcinoid.
Carcinoid tumors are characteristically low grade malignant neoplasms with neuroendocrine differentiation that arise in various body sites, most commonly the lung and gastrointestinal tract, but less frequently the kidneys, breasts, ovaries, testes, prostate and other locations. We report a case of a carcinoid of renal origin with synchronous single liver metastases on radiological studies. A 45 year-old patient who presented with abdominal pain was found on CT scan to have lesions in the right ovary, right kidney, and left hepatic lobe. CA-125, CEA, and CA 19-9 were within normal limits, as were preoperative liver function tests and renal function. Biopsy of the liver mass demonstrated metastatic neuroendocrine tumor. At laparotomy, the patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, radical right nephrectomy with lymphadenectomy, and left hepatectomy. Pathology evaluation reported a right ovarian borderline serous tumor, well-differentiated neuroendocrine carcinoma
The National Comprehensive Cancer Network (NCCN) recommends that tumor differentiation, mitotic rate, and Ki-67 rate be included in the pathology report and that the specific classification and grading scheme be noted to avoid confusion. Clinicians are advised to view histologic grade as a general guide and use clinical judgment to make treatment decisions, particularly in cases of discordance between differentiation and Ki-67 proliferation results. ...
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously ...
Though carcinoids are slow growing tumors, which can be treated by surgery, the survival in metastatic carcinoids is very low because the treatment strategies for other cancers are not effective for dealing with advanced stage carcinoids [36]. Therefore, the investigations concerning the discovery of new strategies for treating pulmonary carcinoids need to be focused on therapies that can inhibit the growth and invasiveness of advanced stage disease. Carcinoid tumors are proving moderately responsive to newer therapies targeting tumor vasculature and survival pathways [1, 2]. The mammalian target of rapamycin (mTOR) inhibitor, everolimus, has shown promising initial results alone or combined with other agents [37-39]. Bronchial AC, which is characterized by high mTOR expression, has been reported to be responders to mTOR inhibition, indicating that therapies targeting the critical survival pathways are potential candidates to treat bronchial carcinoids [40]. The evidence seems to indicate that ...
TY - JOUR. T1 - Treatment of duodenal carcinoid by strip biopsy. AU - Perng, Chin Lin. AU - Lin, Hwai Jeng. AU - Wang, Kun. AU - Lai, Chiung Ru. AU - Lee, Shou Dong. PY - 1995. Y1 - 1995. N2 - In a 70-year-old man with diarrhea and weight loss, upper gastrointestinal endoscopy showed a 0.4-cm nodular lesion at the anterior duodenal bulb with a fissure at the tip of the lesion. The histologic diagnosis of the biopsied specimen revealed a duodenal carcinoid confined to the submucosa. We used strip biopsy to resect the lesion. After resection, diarrhea subsided and weight was increased. Strip biopsy may be a safe and effective choice for management of a duodenal carcinoid if it is AB - In a 70-year-old man with diarrhea and weight loss, upper gastrointestinal endoscopy showed a 0.4-cm nodular lesion at the anterior duodenal bulb with a fissure at the tip of the lesion. The histologic diagnosis of the biopsied specimen revealed a duodenal carcinoid confined to the submucosa. We used strip biopsy to ...
Carcinoid tumors are rare cancerous tumors that are difficult to treat but, if detected early enough, can be cured. These tumors usually begin in the lungs or digestive tract lining. Ideally, they...
Carcinoid tumors are neuroendocrine tumors that originate in the digestive tract, lungs, or rare primary sites, such as kidneys or ovaries. The term carcinoid usually implies a well-differentiated histology and is rarely used to describe high-grade o
Advanced Adult Primary Liver Cancer Carcinoma of the Appendix Estrogen Receptor-negative Breast Cancer Extensive Stage Small Cell Lung Cancer Gastrointestinal Stromal Tumor HER2-negative Breast Cancer Metastatic Gastrointestinal Carcinoid Tumor Ovarian Sarcoma Ovarian Stromal Cancer Progesterone Receptor-negative Breast Cancer Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Adult Primary Liver Cancer Recurrent Anal Cancer Recurrent Basal Cell Carcinoma of the Lip Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor Recurrent Breast Cancer Recurrent Cervical Cancer Recurrent Colon Cancer Recurrent Endometrial Carcinoma Recurrent Esophageal Cancer Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Recurrent Gastric Cancer Recurrent Gastrointestinal Carcinoid Tumor Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Recurrent Lymphoepithelioma of the Nasopharynx ...
Carcinoid tumors are rare, slow growing tumors that are formed by the endocrine cells in the mucosal lining of organs, such as the stomach and intestine. These tumors are small neuroendocrine tumors, typically of the gastrointestinal tract, that secrete serotonin, a naturally occurring neurochemical that is usually associated with sleep and memory functions.
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually , 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of ...
Materials and methods: We performed a phase II trial of axitinib 5 mg BID in patients with advanced low to intermediate grade carcinoid tumors. Prior antiangiogenic therapy with a dedicated VEGF pathway inhibitor was not permitted. The primary endpoints were PFS and 1-year PFS ...
As mentioned above, the occurrence of this syndrome even when the carcinoid tumors are present is very rare as the excess hormones secreted are eliminated by the liver before they dilate the bloodstream. Only in rare cases (where the liver might have also been affected by the tumor), would a person have the chance to develop this syndrome ...
What is Carcinoid Cancer? Get the facts about Carcinoid Cancer symptoms, testing, treatment and care options from trusted sources.
Teaching Files with CT Medical Imaging and case studies on Anatomical Regions including Adrenal, Colon, Cardiac, Stomach, Pediatric, Spleen, Vascular, Kidney, Small Bowel, Liver, Chest | CTisus
A 67-year-old woman with metastatic carcinoid tumor developed neurologic signs and symptoms of left facial paralysis and progressive lower extremity weakness. Results of cytologic evaluation of cerebrospinal fluid were normal. However, biochemical analysis of the cerebrospinal fluid showed extreme elevations of 5-hydroxyindoleacetic acid and serotonin, consistent with carcinomatous meningitis caused by carcinoid tumor. Subsequent contrast myelography confirmed the presence of meningeal metastases. ...
It is with great pleasure that the Carcinoid Cancer Foundation announces that Edward M. Wolin, MD, Co-Medical Director of CCF, has been named Director of the Center for Carcinoid and Neuroendocrine Tumors at The Mount Sinai Hospital in New York City, effective March 26, 2018. Dr. Wolin will be joining Michelle Kang Kim, MD, PhD, Associate Professor of Medicine, Gastroenterology, and Associate Director of the Center, and all the physicians comprising the renowned multidisciplinary NET team at Mount Sinai. With Dr. Wolins arrival he will see patients at Mount Sinai beginning in the spring of 2018 and will bring with him multiple new treatment options and clinical trials.. ...
We have recently reported that activation of the Raf-1/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 (MEK1/2)/ERK1/2 signaling cascade in gastrointestinal carcinoid cell line (BON) alters cellular morphology and neuroendocrine phenotype. The mechanisms by which Raf-1 mediates these changes in carcinoid cells are unclear. Here, we report that activation of the Raf-1 signaling cascade in BON cells induced the expression of focal adhesion kinase (FAK) protein, suppressed the production of neuroendocrine markers, and resulted in significant decreases in cellular adhesion and migration. Importantly, inactivation of MEK1/2 by 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene or abolition of FAK induction in Raf-1-activated BON cells by targeted siRNA led to reversal of the Raf-1-mediated reduction in neuroendocrine markers and cellular adhesion and migration. Phosphorylation site-specific antibodies detected the phosphorylated FAKTyr407, but not ...
Learn about the latest carcinoid tumor treatment and surgery options at MD Anderson Cancer Center. Your treatment is personalized especially for you.
A 42-year-old white woman was seen by her physician because of somatic complaints of the neck and right arm discomfort, difficulty in swallowing, and heartburn. Findings of the workup led to the diagnosis of metastatic ossified gastric carcinoid. R
The angiographic findings of five small intestinal and two colonie carcinoids are described and illustrated, together with a review of the pertinent literature. It is pointed out that the...
Tampa, Florida. We are going to talk about carcinoid disease and diarrhea. We really need to focus closely on this subject. First part of this is about digestion and diarrhea. You know what happens when you put the food in your mouth as it makes its way to your GI tract so we are going to talk about how our intestinal tract works. We process about nine liters of fluid daily and in this picture you can see the little appendage hanging down that is the appendix, but that is where the small intestine and the large intestine join together and that is part of the two feet area that Dr. Kvols discussed where the majority of our gut carcinoids originate.. The small intestines job is to absorb nutrients. That is all that does. We eat the food, it goes into our stomach, it is digested and then the small intestine pulls out all the things that our body needs for metabolic and cellular activity.. Large intestine or your bowel all it does is absorb water. That is its whole job. So this is how diarrhea ...
At present, it is in phase III clinical trials at Novartis for the treatment of carcinoid tumors and symptoms that are not adequately controlled by somatostatin analogues (Sandostatin). Phase II clinical development is also under way at the company for the treatment of gastric dumping syndrome, metastatic carcinoid tumors, meningioma and pituitary adenoma and for the treatment of hepatocellular carcinoma in combination with everolimus. Early clinical trials are also ongoing for the treatment of patients with metastatic melanoma or Merkel cell carcinoma. A phase I clinical trial for the treatment of alcoholic cirrhosis has been completed. The company intends to file for approval in 2007 for these indications. Novartis and Thomas Jefferson University are conducting phase II clinical trials for the treatment of prostate cancer, alone or in combination with everolimus. The Mayo Clinic is conducting phase II clinical trials for the treatment of polycystic liver disease. Phase III clinical trials had ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Common cancers Bladder Cancer Breast Cancer Colorectal Cancer Head and Neck Cancer Kidney Cancer Lung Cancer Lymphoma Melanoma Pancreatic Cancer Prostate Cancer Thyroid Cancer Uterine Cancer AAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)AdenocarcinomaAdrenocortical CarcinomaAIDS-Related LymphomaAnal CancerAppendix Cancer - see Gastrointestinal Carcinoid Tumors BBasal Cell Carcinoma - see Skin Cancer (Nonmelanoma)Bile Duct Cancer, ExtrahepaticBladder CancerBone Cancer […]. ...
Cardiac fibrosis may refer to an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts but more commonly refers to the excess deposition of extracellular matrix in the cardiac muscle. Fibrotic cardiac muscle is stiffer and less compliant and is seen in the progression to heart failure. The description below focuses on a specific mechanism of valvular pathology but there are other causes of valve pathology and fibrosis of the cardiac muscle. Fibrocyte cells normally secrete collagen, and function to provide structural support for the heart. When over-activated this process causes thickening and fibrosis of the valve, with white tissue building up primarily on the tricuspid valve, but also occurring on the pulmonary valve. The thickening and loss of flexibility eventually may lead to valvular dysfunction and right-sided heart failure. Certain diseases such as gastrointestinal carcinoid tumors of the mid-gut, which sometimes release large amounts of ...
Gastrointestinal carcinoid tumor treatment often includes resection of the primary tumor and local lymph nodes. Other treatment options include somatostatin analogs, interferons, treatment of hepatic masses, radionuclides, and symptomatic therapy. Get detailed information in this clinician summary.
A slow growing type of tumor found in the gastrointestinal system, and sometimes in the lungs or other sites. Carcinoid tumors can spread to the liver where they secrete serotonin or prostaglandins, causing carcinoid syndrome.
An ovarian neoplasm characterized by the presence of aberrant thyroid tissue and a carcinoid tumor. A minority of patients develop symptoms of functioning thyroid tissue. The neuroendocrine carcinoid cells infiltrate the aberrant thyroid tissue and progressively replace the follicular lining cells.
Neuroendocrine cells and were first described over a century ago and the term carcinoid was given to them in 1907 by Obendorfer. He described a tumour of the small intestine that grew much more slowly than normal cancers and erroneously classed it as benign. Unfortunately this misunderstanding still permeates throughout the medical community, worldwide. However, in the middle of the 20th century it became evident that these slow-growing tumours could be malignant and spread from the primary site to other parts of the body.. Today, the description carcinoid tumour is being slowly replaced in medical literature by the term NETs or gastroenteropancreatic tumours (GEPs). However, some doctors do still use the term carcinoid tumour or just carcinoid when they refer to NETs that develop in the stomach, duodenum, small intestine, appendix, colon or rectum.. ...
Study population. The study population consisted of patients with histologically confirmed metastatic carcinoid tumor. Other neuroendocrine neoplasms were excluded. Prior therapies, including chemotherapy, immunotherapy, somatostatin analogues, hepatic artery embolization, radiofrequency ablation, and cryoablation, were allowed provided measurable disease remained. Further eligibility criteria included performance status of ≤2 on the Zubrod scale, absolute granulocyte count ,1,500/mm3, hemoglobin ,8 g/dL, platelet count ,100,000/mm3, serum bilirubin ,1.5 times the upper limit of the laboratory normal, serum creatinine ≤1.5 mg/dL, and aspartate aminotransferase and alanine aminotransferase ≤2.5 times the upper limit of the laboratory reference range. Patients with clinically apparent brain metastases and pregnant or lactating women were excluded. Concurrent use of octreotide was allowed.. This study was approved by the Institutional Review Board of M.D. Anderson Cancer Center. All patients ...
Treatment for Carcinoid in Shushrusha Hospital, Mumbai. Find Doctors Near You, Book Appointment, Consult Online, View Doctor Fees, Address, Phone Numbers and Reviews. Doctors for Carcinoid in Shushrusha Hospital, Mumbai | Lybrate
When I was diagnosed 20 years ago (age 22) with carcinoid, it was very difficult to find doctors that were aware of it and how the best to treat it. I was also told that it was very slow growning and only had a soft ball size mass in my left lung. Surgery was performed and all was good for 12 months, then during a routine appointment it was discovered it was in my liver, from there I had it move to my stomach, thyroid and a regrowth in my left lung. Ive went through many surgeries and chemo. 20 years later Im fairly healthy with the minimal issues related to having so many surgeries. This can be beat, I would strongly suggest going to a major hospital that specialies in this type of cancer. I wish you well on our journey. ...
laparotomy that revealed solitary metastasis in the liver, and a hard lesion in the mid-ileum suspicious for the primary carcinoid. A ... the cecum could be secondary to shred wounds . A small lymph node was free of tumor. Left lateral segmentectomy of the liver , .... ...
Surgery, if feasible, is the only curative therapy. If the tumor has metastasized (most commonly, to the liver) and is considered incurable, there are some promising treatment modalities, such as radiolabeled octreotide [5] (e.g. Lutetium (177Lu) DOTA-octreotate) or the radiopharmaceutical 131I-mIBG (meta iodo benzyl guanidine,[5] for arresting the growth of the tumors and prolonging survival in patients with liver metastases, though these are currently experimental.. Chemotherapy is of little benefit and is generally not indicated. Octreotide or Lanreotide (somatostatin analogues) may decrease the secretory activity of the carcinoid, and may also have an anti-proliferative effect. Interferon treatment is also effective, and usually combined with somatostatin analogues.. While the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with CT or MRI, labs for tumor markers, like serotonin, and a history and physical, annual ...
In a sense, the pancreatic cancer research underlying this blog posting is a bookend to the one that we discussed here in the Pancreatica Blog about a month ago. Then, researchers had incorporated the Ki-67 cell proliferation marker into a standard Tumor-Node-Metastasis system (American Joint Committee on Cancer - AJCC) to see if the novel […]. ...
Learn about these slow-growing cancers that usually begin in the digestive system or in the lungs. Treatments include peptide receptor radionuclide therapy.
Eur J Cardiothorac Surg. 2014 Mar;45(3):527-30. doi: 10.1093/ejcts/ezt436. Epub 2013 Sep 18. Case Reports; Research Support, Non-U.S. Govt
Serotonin is metabolized fundamentally to 5-HIAA, mainly by the liver. Digestion system includes first oxidation by monoamine oxidase to the comparing aldehyde. This is trailed by oxidation by aldehyde dehydrogenase to 5-HIAA, the indole acidic corrosive subsidiary. The last is then discharged by the kidneys. One sort of tumor, called carcinoid, some of the time secretes a lot of serotonin into the blood, which causes different manifestations of the carcinoid disorder of flushing (serotonin itself does not result in flushing. Potential reason for flushing in carcinoid disorder incorporate bradykinins, prostaglandins, tachykinins, substance P, and/or histamine), looseness of the bowels, and heart issues. As a result of serotonins development pushing impact on cardiovascular myocytes, a serotonin-emitting carcinoid tumor may cause a tricuspid valve ailment disorder, because of the multiplication of myocytes onto the valve ...
Brief Answer: Most likely a separate problem termed as the Irritable Bowel. Detailed Answer: Hello Dear, Thanks for choosing HealthcareMagic for your query. Ive gone through your details and I appreciate your concerns. Most likely you are suffering from irritable bowel syndrome with overlapping...
Free, official coding info for 2018 ICD-10-CM D3A.010 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
Free, official coding info for 2018 ICD-10-CM D3A.093 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
It started in February when I kept getting bouts of tachycardia even though I have very low blood pressure. I have been getting hot flushing sensations on my chest and face for a few years now and it ...
This is an odd-looking polyp that has a smooth head with some linear vessels extending from its base towards its apex. There appears to be a submucosal component to the polyp as demonstrated by the biopsy forceps in the white-light image (figure 1 [WLI]). The endoscopic diagnosis was of a neuroendocrine tumour (NET), so the lesion was sampled and an abdominal CT requested. The CT scan demonstrated a nodular mass in the terminal ileum (figure 2) and enhancing mesenteric nodal disease (figure 3).. At endoscopy, NETs (previously known as carcinoids) are firm, submucosal nodules with or without an umbilicus. The finding of thicker than usual vessels extending from the base of the polyp towards the apex is a common (but not invariable) pointer to the diagnosis. NETs are neoplasms of the neuroendocrine cells, which are cells widely distributed throughout the body. Although the small intestine is a common site for NETs (16-29% of lesions develop at this site), the absolute incidence is low, ...
A mother of three boys, a daughter, the baby sister to a large family, an aunt, a godmother to several, a trusted friend, an outreach volunteer, a business owner and my wife. Sunny Carney lives up to her name every time someone speaks to her; she is beautiful both in and out. She has been my biggest motivator, my rock and my inspiration in tough times, my biggest fan in good times, and most importantly my best friend. Told 14 years ago that having children may not be part of our future because of ovarian cancer, she kept the faith, and is a wonderful mother to our three sons- Austen, Logan, and Nolan. She is always ensuring that they know the Lord, love of life, kindness to others, hard work, and occasionally when to "shape up". Her boundless energy, healthy lifestyle and positive attitude are infectious. She has served as president of our childrens PTA, organized committees that benefit those who are less fortunate in the community and led drives for those who have been caught up in ...
A mother of three boys, a daughter, the baby sister to a large family, an aunt, a godmother to several, a trusted friend, an outreach volunteer, a business owner and my wife. Sunny Carney lives up to her name every time someone speaks to her; she is beautiful both in and out. She has been my biggest motivator, my rock and my inspiration in tough times, my biggest fan in good times, and most importantly my best friend. Told 14 years ago that having children may not be part of our future because of ovarian cancer, she kept the faith, and is a wonderful mother to our three sons- Austen, Logan, and Nolan. She is always ensuring that they know the Lord, love of life, kindness to others, hard work, and occasionally when to "shape up". Her boundless energy, healthy lifestyle and positive attitude are infectious. She has served as president of our childrens PTA, organized committees that benefit those who are less fortunate in the community and led drives for those who have been caught up in ...
Hi, I want to share a great book covering the subject of living with cancer and making your life extraordinary in the process. Please visit the website for full description and contents. www.i... more ...
If you need to delete a post, please follow the tutorial on the contact page on this link or use the yellow icon ASK TO REMOVE THIS POST in the bottom of the original post ...
Our Wholesale Zebra Print Ribbon Products are great fundraising items to sell to raise money for Carcinoid & Neuroendocrine tumor awareness.
If the whole tumour can be removed, this may cure the cancer and symptoms altogether. But even if surgeons cannot remove the entire tumour, it usually grows slowly and can be controlled with medication.. Overall, people with carcinoid tumours have a good life expectancy compared to many other cancers, with around 70-80% surviving at least five years from diagnosis. Many people remain relatively well and lead active lives, with only occasional symptoms.. But as the tumour grows or spreads, it will produce more and more hormones, and it may eventually be difficult to completely control symptoms with medication. You may need further surgery or other treatments.. Unfortunately, life expectancy is not as good for cancer that has spread to other parts of your body, because it wont usually be possible to remove all of it. However, treatment can still control your symptoms and slow down the spread of cancer.. You can read more about the statistics and outlook for carcinoid on the Cancer Research UK ...
My mother, Catherine Blackwood, was diagnosed with carcinoid cancer in the summer of 2005. Since then, our family and friends have been involved in raising awareness and funds to find a cure. We discovered the Neuroendocrine Tumor Research Foundation very soon after my mothers diagnosis, and have been encouraged by its many resources and its aggressive research plan. I believe that if we work diligently, collaboratively, and creatively enough, that a cure for carcinoid will be found.". ...
Tumors on liver - Liver Cancer: Carcinoid Tumor - St. John Health System. We provides LiverActive Liver Detox formula contains several natural ingredients to help maintain a healthy liver. Listen to your liver and dont ignore the warning signs.
I want you to know that I am sorry for the diagnosis of your father. Unfortunately, it most likely is at 5 centimeters and not .5cms. The problem with lung cancer is, it is one of the most misdiagnosed diseases of our time. Only 25% of all people diagnosed with lung cancer are found in the early stages. Mom was constantly diagnosed with bronchitis for years. In March of 03, her lung collapsed due to Pneumonia, after xrays revealed a mass in her right trachea of her right lung, a bronchoscopy revealed it was actually a 4 cm mass blocking the lung opening completely. She is still with us now, but every day is a miracle. Please be supportive, and cherish every moment you have with him. Believe me, you guys have a very rough road ahead. You have to be strong. I am usually in the chatroom, feel free to Private message me anytime. You may also email me and ask me any questions you are afraid to ask, I am a strong believer of to be forwarned is to be forarmed. Please keep the faith and know that God ...
CASE SUMMARY A 16-year-old girl presented with a 6-month history of intermittent dry cough. For the 2 weeks prior to hospitalization, the patient had tactile...
CASE SUMMARY A 16-year-old girl presented with a 6-month history of intermittent dry cough. For the 2 weeks prior to hospitalization, the patient had tactile...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
When your injury is believed to be in the hypothalamus what is next? How can the damage be determined in the hypothalamus? How are neuroendocrine functions measured? When undergoing this extensive lab work, plan on a minimum of three hours, and often longer. You need to be NPO (nothing by mouth) from 8-12 hours dependent…
ICD-10 CODES AND NARRATIVES C25.4 Malignant neoplasm of endocrine pancreas C7A.00 Malignant carcinoid tumor of unspecified site C7A.010 Malignant carcinoid tumor of the duodenum C7A.011 Malignant carcinoid tumor of the jejunum C7A.012 Malignant carcinoid tumor of the ileum C7A.019 Malignant carcinoid tumor of the small intestine, unspecified portion C7A.020 Malignant carcinoid tumor of the appendix C7A.021 Malignant carcinoid tumor of the cecum C7A.022 Malignant carcinoid tumor of the ascending colon C7A.023 Malignant carcinoid tumor of the transverse colon C7A.024 Malignant carcinoid tumor of the descending colon C7A.025 Malignant carcinoid tumor of the sigmoid colon C7A.026 Malignant carcinoid tumor of the rectum C7A.029 Malignant carcinoid tumor of the large intestine, unspecified portion C7A.090 Malignant carcinoid tumor of the bronchus and lung C7A.091 Malignant carcinoid tumor of the thymus C7A.092 Malignant carcinoid tumor of the stomach C7A.094 Malignant carcinoid tumor of the foregut, ...
Looking for online definition of atypical carcinoid in the Medical Dictionary? atypical carcinoid explanation free. What is atypical carcinoid? Meaning of atypical carcinoid medical term. What does atypical carcinoid mean?
A carcinoid tumor that secretes serotonin or other chemicals into the bloodstream is the cause of carcinoid syndrome. The gastrointestinal tract, including the appendix, colon and rectum, small intestine, stomach, or in the lungs, are some of the places where carcinoid tumors occur most commonly. Carcinoid tumors may develop in the ovaries in some rare cases. The chemicals that cause carcinoid syndrome are secreted only by a small percent of carcinoid tumors, however, these tumors dont have to be advanced to cause carcinoid syndrome. Usually, before these chemicals have a chance to travel through the body and affect it causing symptoms, the liver degrades and neutralizes them in an effective way. But when an advanced tumor spreads (metastasizes) to the liver itself, the chemicals that are secreted by these metastases wont be degraded as efficiently before they reach the bloodstream. Instead of secreting chemicals directly into the liver where the chemicals are processed and eliminated, the ...
Introduction: Carcinoid tumors are neuroendocrine tumors derived from enterochromaffin or Kulchitsky cells (that secretes serotonin or other chemicals into bloodstream), which are widely distributed in the body, but they are traditionally described as originating from the foregut, midgut, and hindgut. A case of carcinoid syndrome is reported.. Case: A 55-year-old man with medical history of Parkinson disease. Was admitted to internal medicine outpatient clinic for with history of diarrhea, abdominal pain, irregular bowel movements dyspepsia and weight loss, asthenia and anorexia, associated with occasional flushing episodes for 10 months. Physical examination revealed: red facial flush and facial spider-like veins and hepatomegaly.. Laboratory: Complete blood count cells was normal. AST 114 U7L. ALT 118 U/l. Bilirrubin 2.1 mg/dl. GGT 482 U/l. ALP 371 U/l.CA-125 52 U/l. Urinary 5-HIAA: 320 mg/24 h (range,10). Chromogranin A ,1200 ng/ml (range,98 ng/ml). Barium enema, filling defect in ileocecal ...
Carcinoid tumors are rare (2.5 to 5.0 cases per 100,000 of the population per year), slow-growing neuroendocrine malignancies with significant potential to produce hepatic metastases and release excessive amounts of vasoactive amines into the systemic circulation (1). As a consequence, up to 15% of patients may develop carcinoid syndrome, with cutaneous flushing, gastrointestinal hypermotility, and cardiac involvement. Cardiac manifestations, also known as carcinoid heart disease (CaHD), are caused by endocardial deposition of pearly fibrotic plaques (notable for absence of elastic fibers) that generally extend to the right-sided valves, leading to multiple patterns of severe valve dysfunction. Plaque formation causes annular constriction, leaflet thickening, and fusion of the subvalvular apparatus. Marked degeneration of the leaflet architecture leads to severe retraction and noncoaptation of the valve, which remains fixed in a semiopen position (2). In this setting, valve replacement is the ...
Another name for Carcinoid Tumor is Carcinoid Syndrome. Facts about carcinoid syndrome: * Carcinoid syndrome is a rare condition * There are less than ...
Find a clinical trial for carcinoid syndrome and carcinoid tumours and sign up to take part. Get links to all you need to know about clinical trials and other useful resources.
Carcinoid tumors of the extrahepatic bile duct. A rare cause of malignant biliary obstruction.: Carcinoid tumor of the bile duct is a rare form of malignant bil
The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea.. Carcinoid syndrome is a cluster of symptoms that occurs in patients with advanced neuroendocrine tumors (NET) and the related diarrhea results from the overproduction of serotonin by these tumors. In addition to discomfort and inconvenience, uncontrolled diarrhea may lead to unwanted weight loss, malnutrition, dehydration, and electrolyte imbalance.. The syndrome is also characterized by facial flushing, abdominal pain, and fatigue. Xermelo is the first and only approved oral therapy for carcinoid syndrome diarrhea that targets the overproduction of serotonin by NET cells, according to a company statement.. The effectiveness of Xermelo was established in a comparative clinical trial in 90 adult participants with well-differentiated NET and carcinoid syndrome diarrhea. ...
4F2hc (CD98) has been associated with tumor growth, and is highly expressed in various tumors. The aim of this study was to evaluate the clinicopathological significance of 4F2hc expression in pulmonary neuroendocrine (NE) tumors. Surgically-resected patient tumors including 16 large cell neuroendocrine carcinoma (LCNEC), 12 small cell lung cancer (SCLC), 1 atypical carcinoid (AC) and 5 typical carcinoid (TC) samples were included in this study. Tumor sections were immunohistochemically stained for 4F2hc (CD98), glucose transporter 1 (Glut1) and 3 (Glut3), hypoxia-inducible factor-1α (HIF-1α), hexokinase I, vascular endothelial growth factor (VEGF), microvessel density (CD34), epidermal growth factor receptor (EGFR), Akt/mammalian target of rapamycin (mTOR) signaling pathway (p-Akt, p-mTOR and p-S6K) and for a cell cycle regulator (p53). 4F2hc was overexpressed in 0% of the pulmonary carcinoids (TCs and ACs), 62.5% of the LCNECs and 50.0% of the SCLCs. A positive 4F2hc expression was ...
BACKGROUND: Recent studies suggest that insulinoma-associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with paired surgical pathology specimens, and to compare its sensitivity and specificity with those of synaptophysin (SYN), chromogranin (CHR), and CD56 for neuroendocrine lung tumors. METHODS: Seventy-four primary lung neoplasms diagnosed on cytology were stained with INSM1, SYN, CHR, and CD56: 41 small cell lung carcinomas (SCLCs), 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma and 1 poorly differentiated non-small cell lung carcinoma, not otherwise specified ...
Lung tumors are neoplastic tumors of the lung These include: Primary tumors of the lung/pulmonary system: Bronchial leiomyoma, a rare, benign tumor Lung cancer, the term commonly used to refer to carcinoma of the lung Pulmonary carcinoid tumor Pleuropulmonary blastoma Neuroendocrine tumors of the lung Lymphomas of the lung. Sarcomas of the lung. Some rare vascular tumors of the lung Non-lung tumors which may grow into the lungs: Mediastinal tumors Pleural tumors Metastasis or secondary tumors/neoplasms with other origin: Metastasis to the lung Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS (2006). "Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings". Radiographics. 26 (1): 41-58. doi:10.1148/rg.261055057. PMID 16418242. [permanent dead link] Giménez A, Franquet T, Prats R, Estrada P, Villalba J, Bagué S (2002). "Unusual primary lung tumors: a radiologic-pathologic overview". Radiographics. 22 (3): 601-19. doi:10.1148/radiographics.22.3.g02ma25601. PMID 12006690. ...
THE WOODLANDS, Texas, Aug. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by severe diarrhea and flushing episodes with long-term consequences including malnutrition, heart disease, and death. Symptoms of carcinoid syndrome have been linked to excess production of serotonin by metastatic tumor cells. Telotristat etiprate is designed to reduce serotonin production.. "Telotristat etiprate is our third drug candidate to demonstrate proof of concept in patients in Phase 2," said Dr. Arthur T. Sands, Lexicons president and CEO. "Based on the positive results of this U.S. study, as well as ...
Mutations of the MEN1 gene located on chromosome 11q13 are associated with the development of a variety of endocrine neoplasms, including parathyroid hyperplasia and adenomas, pituitary adenomas, and pancreatic islet cell tumors. Tumor development is associated with deletion or mutation of the remaining MEN1 allele (1, 2). MEN1 mutations have also been reported in a variety of sporadic endocrine tumors including those commonly seen in multiple endocrine neoplasia syndrome type 1 (MEN1) as well as gastric and pulmonary carcinoid tumors (3). Men1 knockout mice have provided many insights into the role of menin in endocrine homeostasis and tumor suppression (4-7). Although Men1 knockout mice are embryonic lethal, heterozygous mice develop a variety of endocrine tumors similar to those in MEN1 patients. In this model, tumors arising from pancreatic islet cells have been most intensively studied. Heterozygous Men1 knockout mice develop progressive islet cell hyperplasia associated with loss of the ...
...THE WOODLANDS Texas Oct. 21 2011 /- About Carcinoid Syndrome ...Carcinoid syndrome is a chronic condition caused by neuroendocrine tum...,Data,From,Phase,2,Clinical,Studies,of,Telotristat,Etiprate,in,Patients,With,Carcinoid,Syndrome,to,be,Presented,at,North,American,Neuroendocrine,Tumor,Society,Meeting,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Vol 12: A mixture of carcinoid tumors, extensive neuroendocrine proliferation, and multiple pulmonary sclerosing hemangiomas.. This article is from World Journal of Surgical Oncology, volume 12.AbstractWe encountered an extremely rare case of mult. Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Free, official information about 2012 (and also 2013-2015) ICD-9-CM diagnosis code 209.22, including coding notes, detailed descriptions, index cross-references and ICD-10-CM conversion.
Diagnosis Code C7A.022 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Diagnosis Code C7A.098 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Goblet cell carcinoid
Carcinoid Syndrome Symptoms: flushing, diarrhea, heart valvular lesions, cramping, telangiectasia, peripheral edema, wheezing, cyanosis, arthritis, and pellagra. Find more information about Carcinoid Syndrome symptoms here.
Eric Nakakura, M.D., Ph.D., a UCSF gastrointestinal cancer surgeon and Emily Bergsland, M.D.. a UCSF gastrointestinal oncologist, recently discussed the treatment of carcinoid syndrome on "Healthy Body, Healthy Mind", a series hosted by Information Television Network (ITV), a PBS content affiliate. Dr. Nakakura is an Associate Professor in the UCSF Department of Surgery and Dr. Bergsland a Professor in the UCSF Department of Medicine.. The ITV episode, which portrays the struggles of Ray Martz with carcinoid syndrome, recounts the situation he initially faced - that his condition was inoperable, that he would be on a liquid diet indefinitely, and that "nothing further could be done". Unwilling to accept that outcome, Mr. Martz sought treatment at UCSF Medical Center in the the GI Oncology Program, a multidisciplinary team of specialists with extensive experience in diagnosing and treating carcinoid syndrome.. Carcinoid syndrome occurs when a carcinoid tumor, a rare cancerous tumor, secretes an ...
Ipsen Receives Positive CHMP Opinion For Approval Of Xermelo (Telotristat Ethyl), For The Treatment Of Carcinoid Syndrome Diarrhea In Patients Inadequately Controlled By Somatostatin Analogue Therapy - read this article along with other careers information, tips and advice on BioSpace
Cazul prezentat sustine necesitatea abordarii multisectoriale a managementului de caz pentru bolile extrem de rare, asa cum este situatia tumorilor neuroendocrine digestive.
A 54-year-old man who had an appearance strongly suggestive of Cushings syndrome, collapsed after the removal of a carcinoid tumour of the thymus. The clinical suspicion of acute adrenal insufficiency was supported by invasive haemodynamic data and the diagnosis was subsequently confirmed biochemically. These post-operative events were subsequently ignored and a further crisis was probably prevented by tumour recurrence (and hence resumption of adrenocorticotropic hormone (ACTH) production). The ectopic production of ACTH from a carcinoid tumour of the thymus is recognised but a report of acute adrenal insufficiency from its removal is probably unique.. ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
5-HIAA (5-Hydroxyindoleacetic acid) is the major urinary metabolite of serotonin, an ubiquitous bioactive amine. Serotonin, and consequently 5-HIAA, are produced in excess by most carcinoid tumors, especially those producing the carcinoid syndrome. Quantification of urinary 5-HIAA is therefore intended to test for carcinoid ...
The malignant carcinoid syndrome of episodic flushing and diarrhea occurs in association with carcinoid tumors and an elevated urinary level of the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA) (1). Treatment is often directed specifically at diminishing the tumor bulk and includes surgical resection, hepatic artery occlusion, or chemotherapy. Cyproheptadine, a serotonin and histamine antagonist, is often useful in palliating symptoms of the carcinoid syndrome but is not considered to have specific antitumor activity (2). We used cyproheptadine to treat a patient with the carcinoid syndrome. The patient had both symptomatic improvement and an objective partial remission, documented by a fall in ...
Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion ...
TY - JOUR. T1 - Collision tumor of the appendix. T2 - mucinous cystadenoma and carcinoid. A case report. AU - Dellaportas, D.. AU - Vlahos, Nf. AU - Polymeneas, G.. AU - Gkiokas, G.. AU - Dastamani, C.. AU - Carvounis, E.. AU - Theodosopoulos, T.. PY - 2014. Y1 - 2014. N2 - INTRODUCTION: Mucinous cystadenoma is the most common of benign neoplasms of the appendix and carcinoid is the most common type of primary malignant lesions of the appendix.We report a rare case of a 57-year-old female with combined mucinous cystadenoma and carcinoid tumor of the appendix.Dual carcinoid and epithelial neoplasia is a rare occurrence in the appendix.CASE REPORT: A 57-year-old Caucasian woman presented after incidentally palpating a mass on her right iliac fossa. Imaging modalities revealed a cystic tumor in the right iliac fossa with a diameter of about 8 cm, originating either from the right ovary or the appendix. She underwent laparoscopic surgical exploration, which revealed appendiceal mucocele and ...
TY - JOUR. T1 - Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. AU - Rossi, Giulio. AU - Spagnolo, Paolo. AU - Sverzellati, Nicola. AU - Longo, Lucia. AU - Jukna, Agita. AU - Montanari, Gloria. AU - Vincenzi, Giada. AU - Bogina, Giuseppe. AU - Franco, Renato. AU - Tiseo, Marcello. AU - Cottin, Vincent. AU - Colby, Thomas V.. PY - 2016/6/1. Y1 - 2016/6/1. N2 - The term diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) may be used to describe a clinico-pathological syndrome, as well as an incidental finding on histological examination, although there are obvious differences between these two scenarios. According to the World Health Organization, the definition of DIPNECH is purely histological. However, DIPNECH encompasses symptomatic patients with airway disease, as well as asymptomatic patients with neuroendocrine cell hyperplasia associated with multiple tumourlets/carcinoid tumours. DIPNECH is also considered a pre-neoplastic lesion in the spectrum ...
TY - JOUR. T1 - ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. AU - Augustyn, Alexander. AU - Borromeo, Mark. AU - Wang, Tao. AU - Fujimoto, Junya. AU - Shao, Chunli. AU - Dospoy, Patrick D.. AU - Lee, Victoria. AU - Tan, Christopher. AU - Sullivan, James P.. AU - Larsen, Jill E.. AU - Girard, Luc. AU - Behrens, Carmen. AU - Wistuba, Ignacio I.. AU - Xie, Yang. AU - Cobb, Melanie H.. AU - Gazdar, Adi F.. AU - Johnson, Jane E.. AU - Minna, John D.. AU - Vogt, Peter K.. PY - 2014/10/14. Y1 - 2014/10/14. N2 - Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaetescute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is ...
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsens supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA designates priority review status to drug candidates that have the potential to offer a significant improvement in treatment compared to currently approved options. A decision is expected in early 2015.. In the United States, lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. The active substance in the drug is lanreotide acetate, a somatostatin analog that inhibits the secretion of several endocrine, exocrine, and paracrine amines and peptides.. CLARINET Trial. The regulatory submission was supported by the results of the investigational phase III CLARINET study, which demonstrated the ...
Background: We sought to determine if KL-6 is a useful biomarker in differentiating neuroendocrine cell hyperplasia of infancy (NEHI), a benign form of childrens interstitial lung disease, from the more severe inborn errors of surfactant metabolism (IESM), since their clinical presentation can be similar.. Methods: Serum KL-6 levels were measured in 10 healthy control children, 6 with NEHI and 13 with IESM (4 with surfactant protein C and 9 with ABCA3 mutations). The initial clinical presentation, findings on previous CT scans, and ILD scores at the time of KL-6 testing were compared. Correlations between KL-6 levels with age and with interval from lung biopsy were evaluated.. Results: The median (range) KL-6 levels were 265 (1-409), 194 (47-352), 1149 (593-4407) and 3068 (726-9912) for the control, NEHI, SP-C and ABCA3 groups, respectively. When compared to the control and NEHI groups, median KL-6 levels were significantly higher in the SP-C (p,0.01; p=0.01, respectively) and ABCA3 groups ...
Multiple endocrine neoplasia type 1 (MEN1) is characterized by the occurrence of parathyroid, pancreatic islet and anterior pituitary tumors. Some patients may also develop carcinoid tumors, adrenocortical tumors, facial angiofibromas, collagenomas, and lipomas. MEN1 is an autosomal-dominant disorder, due to mutations in the tumor suppressor gene MEN1, which encodes a 610 amino acid protein, menin. Thus, the finding of MEN1 in a patient has important implications for family members because first-degree relatives have a 50% risk of developing the disease and can often be identified by MEN1 mutational analysis. Patients with MEN1 have a decreased life-expectancy and the outcomes of current treatments, which are generally similar to that for the respective tumors occurring in non-MEN1 patients, are not as successful because of multiple tumors, which may be larger, more aggressive, and resistant to treatment, and the concurrence of metastases. The prognosis for MEN1 patients might be improved by pre

Natural History of Familial Carcinoid Tumor - Full Text View - ClinicalTrials.govNatural History of Familial Carcinoid Tumor - Full Text View - ClinicalTrials.gov

People who already have a small bowel carcinoid tumor or are at risk of developing a carcinoid tumor have some or all of the ... Carcinoid Tumor. Neuroendocrine Tumors. Neuroectodermal Tumors. Neoplasms, Germ Cell and Embryonal. Neoplasms by Histologic ... MedlinePlus related topics: Carcinoid Tumors Genetic and Rare Diseases Information Center resources: Carcinoid Tumor ... This includes family members of patients with carcinoid tumors even if the patients with tumors are unwilling to participate so ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00646022?term=familial+AND+carcinoids&rank=1

Factors Associated With Successful Excision of Small Rectal Carcinoid Tumor - SAGES Abstract ArchivesFactors Associated With Successful Excision of Small Rectal Carcinoid Tumor - SAGES Abstract Archives

... and who had colon carcinoid tumors(n=3). Finally, 170 patients with 175 rectal carcinoid tumors, who treated with local ... Factors Associated With Successful Excision of Small Rectal Carcinoid Tumor. Hae Jung Son, MD, Dae Kyung Sohn, MD PhD, Chang ... INTRODUCTION Small rectal carcinoid tumors can be treated by local excision, but complete resection may be difficult because ... METHODS AND PROCEDURES From January 2001 to December 2010, total 299 patients with colorectal carcinoid tumors were treated at ...
more infohttps://www.sages.org/meetings/annual-meeting/abstracts-archive/factors-associated-with-successful-excision-of-small-rectal-carcinoid-tumor/

Germ Cell Origin of Testicular Carcinoid Tumors | Clinical Cancer ResearchGerm Cell Origin of Testicular Carcinoid Tumors | Clinical Cancer Research

Carcinoid tumors also occur in the ovary and it is interesting to compare ovarian carcinoid tumor to testicular carcinoid tumor ... With few exceptions, carcinoid tumors comprise a tiny fraction of tumors within any specific organ (11). These tumors were ... Carcinoid tumors are ∼15 times more common in the ovary than in the testicle. Ovarian carcinoid tumors are most often ... Testicular carcinoid tumor. A to C, case 1; D to F, case 2; G to I, case 3. A, the interface between tumor and adjacent testis ...
more infohttp://clincancerres.aacrjournals.org/content/14/5/1393.long

Pulmonary Carcinoid Tumors: The Need for Tailored Assessment | Cancer Network | The Oncology JournalPulmonary Carcinoid Tumors: The Need for Tailored Assessment | Cancer Network | The Oncology Journal

Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal status. Resected atypical carcinoids ... The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the ... of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to ... Carcinoid tumors have long been considered indolent lesions with a propensity for disseminated disease at diagnosis, ...
more infohttp://www.cancernetwork.com/articles/pulmonary-carcinoid-tumors-need-tailored-assessment

Partial Remission of Carcinoid Tumor in Response to Cyproheptadine | Annals of Internal Medicine | American College of...Partial Remission of Carcinoid Tumor in Response to Cyproheptadine | Annals of Internal Medicine | American College of...

The malignant carcinoid syndrome of episodic flushing and diarrhea occurs in association with carcinoid tumors and an elevated ... Partial Remission of Carcinoid Tumor in Response to Cyproheptadine Stuart P. Leitner, MD; Paul Greenberg, MD; Linda A. Danieu, ... The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas Annals of Internal Medicine; 120 (4): 302- ... Partial Remission of Carcinoid Tumor in Response to Cyproheptadine. Ann Intern Med. 1989;111:760-761. doi: 10.7326/0003-4819- ...
more infohttp://annals.org/aim/article-abstract/703476/partial-remission-carcinoid-tumor-response-cyproheptadine

NAOSITE : Nagasaki Universitys Academic Output SITE: Primary Hepatic Carcinoid Tumor Presenting Carcinoid Syndrome and...NAOSITE : Nagasaki University's Academic Output SITE: Primary Hepatic Carcinoid Tumor Presenting Carcinoid Syndrome and...

Primary Hepatic Carcinoid Tumor Presenting Carcinoid Syndrome and Carcinoid Heart Disease. ファイル. 記述. サイズ. フォーマット. ... Primary Hepatic Carcinoid Tumor Presenting Carcinoid Syndrome and Carcinoid Heart Disease. 著者: Susumu, Seiya / Matsuo, ... These findings led us to the diagnosis of a primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease ... The tumor was histologically and immunohistochemically diagnosed to be a carcinoid tumor. The levels of serum serotonin and ...
more infohttp://naosite.lb.nagasaki-u.ac.jp/dspace/handle/10069/9373

Gastrointestinal carcinoid tumors. Gastroenterology: Diagnostic in Germany, Hamburg hospitals on BookingHealth.comGastrointestinal carcinoid tumors. Gastroenterology: Diagnostic in Germany, Hamburg hospitals on BookingHealth.com

Gastrointestinal carcinoid tumors. Gastroenterology: Diagnostic in Hamburg, Germany ✈. Prices on BookingHealth.com - booking ... Gastrointestinal carcinoid tumors. Diagnostic in Germany, Hamburg See also for gastrointestinal carcinoid tumors:. *Bougienage ... Diagnosis of gastrointestinal carcinoid tumors #239945. The Medical Department I at the University Medical Center Hamburg- ... infectious and tropical diseases and tumor therapy. ...
more infohttps://bookinghealth.com/programs/diagnostic/gastroenterology/gastrointestinal-carcinoid-tumors/germany/hamburg

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome : final...Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome : final...

everolimus, neuroendocrine tumors, carcinoid syndrome, overall survival National Category Cancer and Oncology Identifiers. URN ... Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall ... Endocrine Tumor Biology In the same journal. Annals of Oncology On the subject. Cancer and Oncology Search outside of DiVA. ... Hadassah Hebrew Univ, Med Ctr, Neuroendocrine Tumor Unit, Jerusalem, Israel... Yao, J. C. Univ Texas MD Anderson Canc Ctr, Dept ...
more infohttp://uu.diva-portal.org/smash/record.jsf?pid=diva2:1140646

Carcinoid syndrome | Tumors | ePharmaPediaCarcinoid syndrome | Tumors | ePharmaPedia

If people with carcinoid tumors have a gastrointestinal carcinoid tumor, and particularly if the tumor has spread (metastasized ... The cause of carcinoid tumors is not recognized. A carcinoid tumor that secretes serotonin or other chemicals into the ... The chemicals that cause carcinoid syndrome are secreted only by a small percent of carcinoid tumors, however, these tumors ... the carcinoid lung tumors that secrete them do so much farther upstream. On the other hand, the chemicals of carcinoid tumors ...
more infohttps://epharmapedia.com/diseases/profile/100/Carcinoid-syndrome.html?lang=en

Carcinoid metastasis of the skin appearing as painful tumor - Donati - 2013 - The Journal of Dermatology - Wiley Online LibraryCarcinoid metastasis of the skin appearing as painful tumor - Donati - 2013 - The Journal of Dermatology - Wiley Online Library

The primary cutaneous carcinoid tumor is a very rare disease. The cell of origin for a primary cutaneous carcinoid tumor may be ... Cutaneous involvement of carcinoid tumors is relatively rare, and carcinoid metastases to the skin and subcutaneous tissues are ... Carcinoid tumors are neuroendocrine tumors derived from enterochromaffin cells, which are widely distributed in the body. They ... The patient had a history of pulmonary atypical carcinoid tumor with metastatic hilar lymph node (pT3N1). The pulmonary tumor ...
more infohttp://onlinelibrary.wiley.com/doi/10.1111/1346-8138.12084/full?globalMessage=0

Endocrine Cancers | OSUCCC - JamesEndocrine Cancers | OSUCCC - James

Gastrointestinal Carcinoid Tumors Gastrointestinal carcinoid tumors most often begin in neuroendocrine cells in the ... Pituitary Tumor Pituitary tumors begin in the cells of the pituitary gland - a pea-sized organ located in the bottom center of ... The OSUCCC - James is consistently paving the way in learning more about what causes gastrointestinal carcinoid tumors - ... Gastrointestinal Carcinoid Tumors Treatment Genitourinary Cancers Treatment Gliomas Treatment Gynecologic Cancers Treatment ...
more infohttps://cancer.osu.edu/cancer-specialties/cancer-care-and-treatment/endocrine-cancers

Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical...Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical...

... of all primary lung tumors and can be classified as low grade (typical carcinoids), intermediate grade (atypical carcinoids), ... of all primary lung tumors and can be classified as low grade (typical carcinoids), intermediate grade (atypical carcinoids), ... of all primary lung tumors and can be classified as low grade (typical carcinoids), intermediate grade (atypical carcinoids), ... of all primary lung tumors and can be classified as low grade (typical carcinoids), intermediate grade (atypical carcinoids), ...
more infohttps://einstein.pure.elsevier.com/en/publications/challenges-in-the-diagnosis-and-management-of-well-differentiated

Carcinoid Heart Disease | JACC: Journal of the American College of CardiologyCarcinoid Heart Disease | JACC: Journal of the American College of Cardiology

Carcinoid tumors are rare (2.5 to 5.0 cases per 100,000 of the population per year), slow-growing neuroendocrine malignancies ... The most common primary site of carcinoid tumors is the gastrointestinal tract (60%); one-third of them (34%) arise in the ... Department of Gastroenterology, Center for Carcinoid and Neuroendocrine Tumors, The Mount Sinai Hospital, New York, New York. ... Department of Cardiovascular Surgery, Center for Carcinoid and Neuroendocrine Tumors, The Mount Sinai Hospital, New York, New ...
more infohttp://www.onlinejacc.org/content/66/20/2197

IBC Medical PoliciesIBC Medical Policies

D3A.011 Benign carcinoid tumor of the jejunum D3A.012 Benign carcinoid tumor of the ileum D3A.019 Benign carcinoid tumor of the ... D3A.020 Benign carcinoid tumor of the appendix D3A.021 Benign carcinoid tumor of the cecum D3A.022 Benign carcinoid tumor of ... D3A.091 Benign carcinoid tumor of the thymus D3A.092 Benign carcinoid tumor of the stomach D3A.094 Benign carcinoid tumor of ... D3A.025 Benign carcinoid tumor of the sigmoid colon D3A.026 Benign carcinoid tumor of the rectum D3A.029 Benign carcinoid tumor ...
more infohttp://medpolicy.ibx.com/policies/MedAdvMPI.nsf/6a827f8172ac2f8185257d3100532b7a/85257d39006e7945852584a80057e3aa

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed...Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed...

... tumors in clinical trial on Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are ... New life-saving treatments for Carcinoid tumors , gastrointestinal neoplasms , neuroendocrine ... well-to-moderately differentiated neuroendocrine tumors, including typical carcinoid and pancreatic neuroendocrine tumors, who ... Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard ...
more infohttp://www.centerwatch.com/clinical-trials/listings/98694/neuroendocrine-tumors-study-lanreotide-patients-metastatic/?&radius=50

Carcinoid tumors - Symptoms and causes - Mayo ClinicCarcinoid tumors - Symptoms and causes - Mayo Clinic

Carcinoid tumors in the digestive tract. Signs and symptoms of carcinoid tumors in the digestive tract include:. *Abdominal ... Carcinoid tumors are a type of slow-growing cancer that can arise in several places throughout your body. Carcinoid tumors, ... Carcinoid tumors often dont cause signs and symptoms until late in the disease. Carcinoid tumors can produce and release ... Doctors dont know what causes the mutations that can lead to carcinoid tumors. But they know that carcinoid tumors develop in ...
more infohttps://www.mayoclinic.org/diseases-conditions/carcinoid-tumors/symptoms-causes/syc-20351039

Carcinoid Tumor News, ResearchCarcinoid Tumor News, Research

... the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor ... or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone. ... Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors A Novartis ... AACR invites application for carcinoid and pancreatic neuroendocrine tumor research grant The American Association for Cancer ...
more infohttps://www.news-medical.net/?tag=/Carcinoid-Tumor

Typical pulmonary carcinoid tumour - WikipediaTypical pulmonary carcinoid tumour - Wikipedia

Typical pulmonary carcinoid tumour is a subtype of pulmonary carcinoid tumour. It is an uncommon low-grade malignant lung mass ... The differential diagnosis of typical pulmonary carcinoid tumour includes: atypical pulmonary carcinoid tumour, pulmonary ... It is also known as typical lung carcinoid tumour, lung carcinoid, and typical lung carcinoid. ... Nov 2011). "CT features of peripheral pulmonary carcinoid tumors". AJR Am J Roentgenol. 197 (5): 1073-80. doi:10.2214/AJR. ...
more infohttps://en.wikipedia.org/wiki/Typical_pulmonary_carcinoid_tumour

Carcinoid tumors? - Gastroenterology - MedHelpCarcinoid tumors? - Gastroenterology - MedHelp

Carcinoid tumors?. It started in February when I kept getting bouts of tachycardia even though I have very low blood pressure. ... The chances of you having a carcinoid tumor in your small intestine that has spread all over your body giving you these ... The chances of you having a carcinoid tumor in your small intestine that has spread all over your body giving you these ... I think that you and your doctor can comfortably completely eliminate the possibility of a metastasized carcinoid tumor in your ...
more infohttp://www.medhelp.org/posts/Gastroenterology/Carcinoid-tumors/show/1762310

Gastrointestinal Carcinoid Tumor Surgery | MoffittGastrointestinal Carcinoid Tumor Surgery | Moffitt

Surgery may be recommended to remove a gastrointestinal carcinoid tumor, as well as any nearby lymph nodes or tissues that also ... The most common types of gastrointestinal carcinoid tumor surgery include:. *A local excision, which involves the removal of ... A complete or partial resection of the organ in which the carcinoid tumor developed, such as the bowel, liver, stomach, ... There are several different surgeries that can be recommended for a patient with a gastrointestinal carcinoid tumor; the most ...
more infohttps://moffitt.org/cancers/gastrointestinal-carcinoid-tumor/surgery/

Intestinal Carcinoid Tumor: Practice Essentials, Background, PathophysiologyIntestinal Carcinoid Tumor: Practice Essentials, Background, Pathophysiology

... a well-differentiated neuroendocrine tumor, is the most common distal small bowel malignancy, with an occurrence rate of one ... In addition, carcinoid tumors may coexist with other endocrine tumors. Tumors that histologically appear to be carcinoids may ... encoded search term (Intestinal Carcinoid Tumor) and Intestinal Carcinoid Tumor What to Read Next on Medscape. Related ... The occurrence rate of carcinoid tumors peaks at approximately age 62 years. Carcinoid tumors are rare in young persons, ...
more infohttps://emedicine.medscape.com/article/276837-overview

Carcinoid Tumors: MedlinePlusCarcinoid Tumors: MedlinePlus

Carcinoid tumors can happen in the lungs or digestive tract. Learn about risk factors, tests, treatment, and more. ... How Are Lung Carcinoid Tumors Diagnosed? (American Cancer Society) * How Are Lung Carcinoid Tumors Staged? (American Cancer ... What Are Lung Carcinoid Tumors? (American Cancer Society) * What Is a Gastrointestinal Carcinoid Tumor? (American Cancer ... Lung Carcinoid Tumor: Surgery (American Cancer Society) * Treatment of Gastrointestinal Carcinoid Tumors by Stage (American ...
more infohttps://medlineplus.gov/carcinoidtumors.html

Carcinoid TumorsCarcinoid Tumors

... are small growths usually found in the intestinal tract. Carcinoid tumors are noncancerous ... Therefore, carcinoid tumors that originate in the digestive tract generally do not produce symptoms unless the tumors have ... MRI or CT can be helpful in confirming whether the tumor has spread to the liver. Treatment When a carcinoid tumor is ... Symptoms Most people with carcinoid tumors have symptoms similar to those of other intestinal tumors, mainly cramping pain and ...
more infohttp://www.psyweb.com/Glossary/carcinoidtumors.jsp

What are carcinoid tumors? | Reference.comWhat are carcinoid tumors? | Reference.com

These tumors usually begin in the lungs or digestive tract lining. Ideally, they... ... Carcinoid tumors are rare cancerous tumors that are difficult to treat but, if detected early enough, can be cured. ... What is the prognosis and natural history of carcinoid tumors?. A: Carcinoid tumors are growths that originate from hormone ... What is the life expectancy of a patient diagnosed with a carcinoid tumor?. A: There are different survival rates for carcinoid ...
more infohttps://www.reference.com/health/carcinoid-tumors-407ba48cdea89add

Carcinoid Tumor Treatment | MD Anderson Cancer CenterCarcinoid Tumor Treatment | MD Anderson Cancer Center

Learn about the latest carcinoid tumor treatment and surgery options at MD Anderson Cancer Center. Your treatment is ... Carcinoid Tumor Treatment. At MD Anderson, your treatment for carcinoid tumor is personalized especially for you. A team of ... Our Carcinoid Tumor Treatments. If you are diagnosed with a carcinoid tumor, your doctor will discuss the best options to treat ... a common site of carcinoid tumors.. Radiofrequency ablation and cryoablation: These methods to destroy carcinoid tumors in the ...
more infohttps://www.mdanderson.org/cancer-types/carcinoid-tumors/carcinoid-tumor-treatment.html
  • Among of them, we excluded patients who had metastatic disease(n=10), who underewent radical operation(n=33), who were diagnosed in other hospitals(n=83) and who had colon carcinoid tumors(n=3). (sages.org)
  • The specialists of the Department have a special experience in the treatment of gastrointestinal diseases, liver and pancreatic diseases, infectious and tropical diseases and tumor therapy. (bookinghealth.com)
  • INTRODUCTION Small rectal carcinoid tumors can be treated by local excision, but complete resection may be difficult because tumors are located in the submucosal layer. (sages.org)
  • We performed this study to find out the risk factors associated with pathologically complete resection of rectal carcinoid tumor. (sages.org)
  • A pathologically complete resection(P-CR) was defined as an en bloc resection with tumor-free lateral and deep margin. (sages.org)
  • CONCLUSIONS Advanced endoscopic technique or surgical local excision was more beneficial to achieve pathologically complete resection than conventional polypectomy in local treatment of small rectal carcinoid tumors. (sages.org)
  • METHODS AND PROCEDURES From January 2001 to December 2010, total 299 patients with colorectal carcinoid tumors were treated at the National Cancer Center, South Korea. (sages.org)
  • Finally, 170 patients with 175 rectal carcinoid tumors, who treated with local excision including endoscopic resection and surgical resection were enrolled this study. (sages.org)
  • We evaluated the P-CR rate according to treatment method, tumor size, endoscopically initial impression and use of endoscopic ultrasound(EUS) or transrectal ultrasound(TRUS). (sages.org)
  • Common diagnostic tests the physician may order to confirm the diagnosis of carcinoid tumor include blood tests to detect elevated levels of a protein caused by hormones secreted by the carcinoid tumor, urine tests to identify increased levels of a chemical from hormones broken down by the carcinoid tumor, imaging tests, endoscopy, or biopsy. (fortherecordmag.com)
  • The diagnosis of carcinoid tumor is initially based on histology with confirmation by positive immunohistochemical staining, defined as positive staining for one or more neuroendocrine markers (such as chromogranin A or synaptophysin), or electron microscopy in which the cells in most tumors are found to contain membrane-bound secretory granules with dense-core granules in the cytoplasm [ 9 ]. (pubmedcentralcanada.ca)
  • Reuter SR, Boijsen E: Angiographic findings in two ileal carcinoid tumors. (springer.com)
  • Although Theodor Langhans (1839-1915) was the first to describe the histology of a carcinoid tumor in 1867 [ 1 ], it is generally Otto Lubarsch (1860-1933) who is credited with the first report of 2 patients with ileal carcinoid tumors discovered at autopsy, in 1888 [ 2 - 3 ]. (pubmedcentralcanada.ca)
  • Even though the frequency of the primary tumor is high, the incidence of metastasis is quite low (one metastasis per 300,000 cases). (medscape.com)
  • The incidence of primary renal carcinoids is very low, and only 62 cases have been reported in the English literature. (urotoday.com)
  • These tumors usually begin in the lungs or digestive tract lining. (reference.com)
  • Carcinoid cancer is a slow-growing type of cancer that typically begins in the lining of the lungs or the digestive tract, according to the National Instit. (reference.com)
  • A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone. (news-medical.net)
  • For the diagnosis of chest tumors, CT combined with scintigraphy with octreotide is preferred. (medscape.com)
  • Scintigraphy with MIBG and octreotide scanning have been used to successfully detect carcinoid tumors. (medscape.com)
  • Sometimes octreotide can temporarily shrink carcinoid tumors, but it does not cure them. (cancer.org)
  • The Octreotide/Sandostatin is an option,but Chemo is not a viable one with carcinoid patients, and The Oncologist wants to monitor the labs before any such treatment begins. (healingwell.com)
  • Hormone Therapy - if surgery doesn't work, your doctor might try injections of a synthetic hormone called octreotide to slow the growth of the tumor. (mercy.com)
  • Carcinoids follow a more benign clinical course than most other malignancies. (medscape.com)
  • Carcinoid tumors are noncancerous ( benign ) or cancerous ( malignant ) growths that produce excessive amounts of hormonelike substances. (psyweb.com)
  • Carcinoid tumors, a subgroup of neuroendocrine tumors, are biologically different from other types of cancer and can be either malignant or benign. (fortherecordmag.com)
  • The fourth and fifth digits identify the specific location of the carcinoid tumor and whether it is malignant or benign. (fortherecordmag.com)
  • In 1907, Siegfried Obendorfer (1876-1944), a German pathologist at the University of Munich, coined the term karzinoide , or "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite resembling a carcinoma microscopically [ 4 ]. (pubmedcentralcanada.ca)
  • Carcinoid tumors were initially identified in 1888 and were thought to clinically and histologically (cellular appearance under a microscope) resemble carcinoma cells (highly malignant cancer cells) but behave in a more benign fashion than true cancer cells. (medifocus.com)
  • The tumors grow so slowly that even people whose tumors have spread often survive for 10 to 15 years. (psyweb.com)
  • Nonhormonal manifestations vary according to the location of the primary tumor. (medscape.com)
  • It may be used to treat the primary tumor and nearby lymph nodes where the cancer has spread. (mdanderson.org)
  • Removal of the mesentery is at least as important as removing the primary tumor. (mdanderson.org)
  • As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. (medlineplus.gov)
  • If you're worried that you may have a digestive tract tumor, schedule a visit with your doctor. (mercy.com)
  • Some tumors are slow-growing and can remain unseen for a long time, so it's important to let your doctor know if you have any new signs or symptoms after you recover from a digestive tract tumor. (mercy.com)
  • The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research. (news-medical.net)
  • In a recent issue of Pancreas, official journal of the American Pancreatic Association, presents the newly developed consensus guidelines of the North American Neuroendocrine Tumor Society (NANETS). (news-medical.net)
  • 258.01), patients develop parathyroid, pancreatic, and adrenal tumors as well as gastrinomas and insulinomas. (fortherecordmag.com)
  • Treatment depends on the type and severity of the tumors and includes the management of complications related to tumors and may include surgical resection. (fortherecordmag.com)